(Q36147082)

English

5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents?

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

1 reference

Europe PubMed Central

5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents? (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

1 reference

based on heuristic

inferred from title

author name string

Matti Aapro

1

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

Peter Blower

2

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

language of work or name

0 references

publication date

1 July 2005

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

104

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

1-18

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

21 January 2018

Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

21 January 2018

The influence of ethnicity and antidepressant pharmacogenetics in the treatment of depression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

21 January 2018

Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. The Granisetron Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

21 January 2018

Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetr

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

21 January 2018

Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

21 January 2018

The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

21 January 2018

Absence of excess peripheral muscle fatigue during beta-adrenoceptor blockade.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

21 January 2018

Measuring chemotherapy-induced nausea and emesis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

The severity and pattern of emesis following different cytotoxic agents

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

ASHP Therapeutic Guidelines on the Pharmacologic Management of Nausea and Vomiting in Adult and Pediatric Patients Receiving Chemotherapy or Radiation Therapy or Undergoing Surgery

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiemetic guidelines: creating a more practical treatment approach

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Nausea and vomiting as major complications of cancer chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

On the receiving end--patient perception of the side-effects of cancer chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensity of chemotherapy-induced emesis and overall survival as determinants of a global utility score.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Incidence of chemotherapy-induced nausea and emesis after modern antiemetics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Stratified administration of serotonin 5-HT3 receptor antagonists (setrons) for chemotherapy-induced emesis. Economic implications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administration

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Differentiation of Na(+)-K+ pumps of low-K+ sheep red blood cells is promoted by Lp membrane antigens

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Allosteric interactions among agonists and antagonists at 5-hydroxytryptamine3 receptors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

5-hydroxytryptamine3 (5-HT3) receptor-mediated depolarisation of the rat isolated vagus nerve: modulation by trichloroethanol and related alcohols.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Allosteric potentiation of the 5-HT3 receptor-mediated ion current in N1E-115 neuroblastoma cells by 5-hydroxyindole and analogues

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Modulation of nicotinic ACh-, GABAA- and 5-HT3-receptor functions by external H-7, a protein kinase inhibitor, in rat sensory neurones

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Pretreatment factors predicting the development of postchemotherapy nausea and vomiting in Chinese breast cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Chimaeric nicotinic-serotonergic receptor combines distinct ligand binding and channel specificities.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

5-HT3-receptor antagonists and the cytochrome P450 system: clinical implications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Are all 5-HT3 receptor antagonists the same?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Intravenous granisetron--establishing the optimal dose. The Granisetron Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Granisetron: is there a dose-response effect on nausea and vomiting?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral granisetron--simple and effective: a preliminary report. The Granisetron Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiemetic treatment with oral granisetron in patients receiving moderately emetogenic chemotherapy: a dose-ranging study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Em

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized open-label trial of dolasetron for the control of nausea and vomiting associated with high-dose chemotherapy with hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral serotonin type 3-receptor antagonists for prevention of chemotherapy-induced emesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-finding study of tropisetron in cisplatin-induced nausea and vomiting

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, double-blind, multicentre study comparing daily 2 and 5 mg of tropisetron for the control of nausea and vomiting induced by low-dose cisplatin- or non-cisplatin-containing chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. The Ondansetron and Granisetron Emesis Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy—A randomised study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiemetic effectiveness of ondansetron and granisetron in patients with breast cancer treated with cyclophosphamide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

A multicenter, double-blind, randomized comparison of oral ondansetron 8 mg b.i.d., 24 mg q.d., and 32 mg q.d. in the prevention of nausea and vomiting associated with highly emetogenic chemotherapy. S3AA3012 Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of granisetron in patients refractory to previous treatment with antiemetics.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Granisetron vs ondansetron: is it a question of duration of 5-HT3 receptor blockade?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Current position of 5HT3 antagonists and the additional value of NK1 antagonists; a new class of antiemetics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

BRL 46470 potently antagonizes neural responses activated by 5-HT3 receptors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

The pattern of emesis following high-dose cyclophosphamide and the anti-emetic efficacy of ondansetron

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Modulation by 5-HT3 and 5-HT4 receptors of the release of 5-hydroxytryptamine from the guinea-pig small intestine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21141

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.21141

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36147082&oldid=1967179682"